electroCore, Inc. Common Stock
ECORelectroCore, Inc. is a biotechnology company focused on developing non-invasive neuromodulation therapies. Known for their FDA-approved device, gammaCore, they aim to treat various conditions such as migraines and cluster headaches through its innovative vagus nerve stimulation technology.
Company News
electroCore, Inc. (Nasdaq: ECOR), a bioelectronic medicine company, announced it will present at Planet MicroCap Las Vegas 2026 on June 17-18 at the Bellagio Resort & Casino. Joshua Lev, Interim President and CFO, will deliver a presentation and host one-on-one investor meetings to discuss the company's strategy and growth opportunities.
electroCore, Inc. (Nasdaq: ECOR) announced its participation in the LD Micro Invitational XVI Conference on May 18, 2026, in Los Angeles. Interim President and CFO Joshua Lev will present and conduct one-on-one meetings. The company reported Q1 2026 net sales of $9.6 million, up 43% year-over-year, though it posted a net loss of $5.3 million with...
electroCore, Inc. (Nasdaq: ECOR), a bioelectronic medicine company, announced its participation in the Market Movers Investor Summit on May 5, 2026, at the Bank of New York in New York City. Joshua Lev, Interim President and CFO, will deliver a presentation and conduct one-on-one investor meetings.
electroCore published clinical findings in Frontiers in Neuroscience demonstrating that adjunctive non-invasive vagus nerve stimulation (nVNS) significantly reduced symptom burden in 35 patients with chronic mild traumatic brain injury and comorbid PTSD, showing improvements across cognitive, affective, and somatic domains.
electroCore announced a new research initiative with Acacia Clinics and the Vagus Nerve Society to study gammaCore Sapphire, a non-invasive vagus nerve stimulator, as an adjunctive treatment for PTSD symptoms. The 10-month study will enroll up to 40 subjects aged 18-70 and measure safety and efficacy using clinical assessment scales. electroCore ...
